Patent ID: 7384965

Claim:
A compound of the structural Formula: and stereoisomers, pharmaceutically acceptable salts, solvates and hydrates thereof, wherein: (a) R26 and R27, are each independently selected from the group consisting of hydrogen, hydroxy, cyano, nitro, halo, oxo, C 1 -C 6 alkyl, C 1 -C 6 alkyl-COOR12, C 1 -C 6 alkoxy, C 1 -C 6 haloalkyl, C 1 -C 6 haloalkyloxy, C 3 -C 7 cycloalkyl, aryloxy, aryl-C 0-4 -alkyl, heteroaryl, heterocycloalkyl, C(O)R13, COOR14, OC(O)R15, OS(O) 2 R16, N(R17) 2 , NR18C(O)R19, NR20SO 2 R21, SR22, S(O)R23, S(O) 2 R24, and S(O) 2 N(R25) 2 ; R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24 and R25 are each independently selected from the group consisting of hydrogen, C 1 -C 6 alkyl and aryl; (b) X is selected from the group consisting of a single bond, O, S, S(O) 2 and N; (c) U is an aliphatic linker of C 1 -C 3 alkyl (d) Y is selected from the group consisting of C, O, S, NH, and a single bond; (e) E is C(R3)(R4)A and wherein (i) A is selected from the group consisting of carboxyl, C 1 -C 6 alkylnitrile, carboxamide, sulfonamide and acylsulfonamide; wherein sulfonamide, and acylsulfonamide are each optionally substituted with from one to two groups independently selected from R 7 ; (ii) each R 7 is independently selected from the group consisting of hydrogen, C 1 -C 6 haloalkyl, aryl C 0 -C 4 alkyl and C 1 -C 6 alkyl; (iii) R3 is selected from the group consisting of hydrogen, C 1 -C 5 alkyl,; and (iv) R4 is selected from the group consisting of H, and C 1 -C 5 alkyl, and R3 and R4 are optionally combined to form a C 3 -C 4 cycloalkyl, and wherein alkyl, are each optionally substituted with one to three substituents each independently selected from R26; (f) B is selected from the group consisting of S, and O; (g) Z is N; (h) R8 is selected from the group consisting of hydrogen, C 1 -C 4 alkyl, C 1 -C 4 alkylenyl, and halo; (i) R9 is selected from the group consisting of hydrogen, C 1 -C 4 alkyl, C 1 -C 4 alkylenyl, halo, aryl-C 0 -C 4 alkyl, andaryl, and wherein aryl-C 0 -C 4 alkyl, is optionally substituted with from one to three independently selected from R27; R8 and R9 optionally combine to form a five membered fused bicyclic with the phenyl to which R8 and R9 attach, provided that when R8 and R9 form a fused ring, the group E-Y— is bonded at any available position on the five membered ring of such R8 and R9 fused bicyclic; (j) R10, R11 are each independently selected from the group consisting of hydrogen, hydroxy, cyano, nitro, halo, oxo, C 1 -C 6 alkyl, C 0 -C 6 alkoxy, and C 1 -C 6 haloalkyl, (k) R32 is selected from the group consisting of a bond, hydrogen, halo, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, and C 1 -C 6 alkyloxo; (l) AL is a fused C 3 -C 8 carbocyclic and; (m) — is optionally a bond to form a double bond at the indicated position.